Browsing by Author "Aydogdu I."
Now showing 1 - 20 of 20
Results Per Page
Sort Options
Item Analysis of Swarm Intelligence-Based Algorithms for Constrained Optimization(Elsevier Inc., 2013) Saka M.P.; Doǧan E.; Aydogdu I.Swarm intelligence refers to collective intelligence. Biologists and natural scientist have been studying the behavior of social insects due to their efficiency of solving complex problems such as finding the shortest path between their nest and food source or organizing their nests. In spite of the fact that these insects are unsophisticated individually, they make wonders as a swarm by interaction with each other and their environment. In last two decades, the behaviors of various swarms that are used in finding preys or mating are simulated into a numerical optimization technique. In this chapter, eight different swarm intelligence-based algorithms are summarized and their working steps are listed. These techniques are ant colony optimizer, particle swarm optimizer, artificial bee colony algorithm, glowworm algorithm, firefly algorithm, cuckoo search algorithm, bat algorithm, and hunting search algorithm. Two optimization problems taken from the literature are solved by all these eight algorithms and their performance are compared. It is noticed that most of the swarm intelligence-based algorithms are simple and robust techniques that determine the optimum solution of optimization problems efficiently without requiring much of a mathematical struggling. © 2013 Copyright © 2013 Elsevier Inc. All rights reserved.Item Analysis of Swarm Intelligence-Based Algorithms for Constrained Optimization(Elsevier, 2013) Saka M.P.; Dogan E.; Aydogdu I.Swarm intelligence refers to collective intelligence. Biologists and natural scientist have been studying the behavior of social insects due to their efficiency of solving complex problems such as finding the shortest path between their nest and food source or organizing their nests. In spite of the fact that these insects are unsophisticated individually, they make wonders as a swarm by interaction with each other and their environment. In last two decades, the behaviors of various swarms that are used in finding preys or mating are simulated into a numerical optimization technique. In this chapter, eight different swarm intelligence-based algorithms are summarized and their working steps are listed. These techniques are ant colony optimizer, particle swarm optimizer, artificial bee colony algorithm, glowworm algorithm, firefly algorithm, cuckoo search algorithm, bat algorithm, and hunting search algorithm. Two optimization problems taken from the literature are solved by all these eight algorithms and their performance are compared. It is noticed that most of the swarm intelligence-based algorithms are simple and robust techniques that determine the optimum solution of optimization problems efficiently without requiring much of a mathematical struggling. © 2013 Elsevier Inc. All rights reserved.Item Clinical characteristics, post-treatment assessment and prognostic factors affecting patient survival of patients at 65 years of age or older with hodgkin lymphoma: A retrospective multicenter study from Turkey(A. CARBONE Editore, 2015) Berber I.; Erkurt M.A.; Keklik M.; Dogu M.H.; Terzi H.; Pala C.; Sari H.I.; Sencan M.; Sivgin S.; Hacioglu S.; Altuntas F.; Aydogdu I.; Ilhan O.Introduction: During the last three decades, major advances have been made in the therapy of Hodgkin's lymphoma. However, despite these advances, Hodgkin's lymphoma has a poor prognosis in the elderly. The proportion of Hodgkin's lymphoma patients aged > 60 ranges in the different reports between 15% and 35%. This study aimed to examine clinical characteristics, treatment outcomes and prognostic factors affecting patient survival in Hodgkin's lymphoma patients aged 65 years or older. Material methods: Hodgkin's lymphoma patients at 65 years of age and older managed within last 5 years in a total of 5 centers in Turkey were retrospectively assessed. Results: The median age of a total of 32 patients was 71 (65-83) years. Elderly patients presented more frequently with B symptoms, elevated sedimentation rate, mixed cellularity histologic subtype and comorbid disease. Less frequent were bulky disease, bone marrow involvement, and the application of autologous stem cell transplantation. The nodular lymphocyte predominant subtype and lymphocyte rich subtype were not observed at all. Eastern Cooperative Oncology Group, ferritin, total protein, and histological type were significant predictors affecting survival (p<0.05). Conclusions: Hodgkin's lymphoma is a more fatal disease in 65 years of age or older, when compared to the young population. Tumor biology, older age itself, and other factors related to comorbidity probably contribute to the worse outcome of elderly patients. Further large-scale studies are needed to better investigate the factors that were significant predictors of patient survival.Item Multicenter retrospective analysis regarding the clinical manifestations and treatment results in patients with hairy cell leukemia: Twenty-four year Turkish experience in cladribine therapy(John Wiley and Sons Ltd, 2015) Hacioglu S.; Bilen Y.; Eser A.; Sivgin S.; Gurkan E.; Yildirim R.; Aydogdu I.; Dogu M.H.; Yilmaz M.; Kayikci O.; Tombak A.; Kuku I.; Celebi H.; Akay M.O.; Esen R.; Korkmaz S.; Keskin A.In this multicenter retrospective analysis, we aimed to present clinical, laboratory and treatment results of 94 patients with Hairy cell leukemia diagnosed in 13 centers between 1990 and 2014. Sixty-six of the patients were males and 28 were females, with a median age of 55. Splenomegaly was present in 93.5% of cases at diagnosis. The laboratory findings that came into prominence were pancytopenia with grade 3 bone marrow fibrosis. Most of the patients with an indication for treatment were treated with cladribine as first-line treatment. Total and complete response of cladribine was 97.3% and 80.7%. The relapse rate after cladribine was 16.6%, and treatment related mortality was 2.5%. Most preferred therapy (95%) was again cladribine at second-line, and third line with CR rate of 68.4% and 66.6%, respectively. The 28-month median OS was 91.7% in all patients and 25-month median OS 96% for patients who were given cladribine as first-line therapy. In conclusion, the first multicenter retrospective Turkish study where patients with HCL were followed up for a long period has revealed demographic characteristics of patients with HCL, and confirmed that cladribine treatment might be safe and effective in a relatively large series of the Turkish study population. © 2015 John Wiley & Sons, Ltd.Item Square IgM crystals in bone marrow in Waldenström macroglobulinaemia(Blackwell Publishing Ltd, 2016) Erdem N.; Ulu I.; Miskioglu H.M.; Isisag A.; Aydogdu I.[No abstract available]Item Primary central nervous system lymphoma in daily practice and the role of autologous stem cell transplantation in relapsed disease: A retrospective multicenter study(Elsevier Ltd, 2016) Erkurt M.A.; Berber I.; Tekgündüz E.; Dogu M.H.; Korkmaz S.; Demir C.; Yilmaz M.; Akay O.M.; Pala C.; Bilen Y.; Kaya E.; Sari I.; Sencan M.; Kuku I.; Altuntaş F.; Dal M.S.; Aydogdu I.We investigated the course of 54 patients presenting with primary central nervous system lymphoma, who were treated in daily practice. The patients were treated with chemotherapy and/or radiotherapy and/or intrathecal chemotherapy. At a median follow-up period of 23 months (range 1-71), median relapse-free survival (RFS) and overall survival (OS) were not reached. Estimated 2-year RFS and OS rates were 42% and 48%, respectively. Ten relapsed PCNSL patients underwent ASCT. Complete remission rate of these patients was 40%, with 20% treatment-related mortality. Estimated 2-year RFS and OS rates were 37% and 40%, respectively. The prognosis of patients with PCNSL, who received off-study treatment, is still dismal. © 2016 Elsevier Ltd.Item Actual reason for bone fractures in the case of a patient followed-up with the osteogenesis imperfecta: Gaucher's Disease(CIC Edizioni Internazionali s.r.l., 2017) Demirci U.; Çizmecioglu A.; Aydogdu I.Gaucher's disease (GD) is a rare disease characterized by a glucocerebroside accumulation in the reticulo-endothelial system. Patients may refer to the clinic with complaints of bone pain, hepatosplenomegaly, anemia, thrombocytopenia, growth retardation, interstitial pulmonary disease, pulmonary hypertension, and skeletal disorders. Skeletal system involvement is observed commonly in Gaucher patients and a significant cause of morbidity. Our patient was followed for several years as a glass child - osteogenesis imperfecta and he had joint deformities due to skeletal fractures. We wanted to present this case to raise awareness of GD's skeletal involvement and effects of late diagnosis.Item Enzyme Replacement Therapy in a Gaucher Family(National Medical Association, 2018) Erdem N.; Buran T.; Berber I.; Aydogdu I.Gaucher disease is a lipid storage disorder due to deficiency of beta glucocerebrosidase. It's an autosomal recessive disease and as a result of this enzyme deficiency, glucocerebroside accumulates in various types of tissues like liver, brain spleen and bone marrow. We aimed to describe the effects of enzyme replacement therapy in three members of a family with Gaucher disease and to emphasize screening of the family members of the patients with Gaucher disease. Furthermore, late diagnosis and treatment in these patients have a minimal effect on improvement of the quality of life, and early diagnosis and treatment are very important in Gaucher disease. © 2017 National Medical AssociationItem A rare parasitic infection: visceral leishmaniasis case after gastric cancer treatment(Springer-Verlag Wien, 2018) Yolcu A.; Dirican A.; Ozturk G.G.; Cetin C.B.; Aydogdu I.We present a case of Visceral Leishmaniasis (VL) in a patient with gastric cancer treated with chemoradiotherapy. A 69-year-old man with gastric carcinoma had been treated with total gastrectomy, lymphadenectomy and postoperative radiotherapy with chemotherapy. Then 3 years after treatment, due to pancytopenia with progressive trombocytopenia and splenomegaly, bone marrow examination was performed and Leishmania spp. amastigotes were diagnosed. When antibiotherapy was completed, splenomegaly was eliminated and the laboratory results became normal. VL should be kept in mind in the differential diagnosis of patients, even adults, with splenomegaly, trombocytopenia and a history of contact with dogs in endemic countries such as Turkey. © 2018, Springer-Verlag GmbH Austria, part of Springer Nature.Item Nodular lymphocyte predominant Hodgkin's lymphoma in daily practice: A multicenter experience(John Wiley and Sons Ltd, 2018) Gemici A.; Aydogdu I.; Terzi H.; Sencan M.; Aslan A.; Kaya A.H.; Dal M.S.; Akay M.O.; Dogu M.H.; Ayyildiz O.; Sahin F.; Cagliyan G.A.; Yilmaz M.; Gokgoz Z.; Bilen Y.; Demir C.; Sevindik O.G.; Korkmaz S.; Eser B.; Altuntas F.Nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) is a rare subtype of Hodgkin's lymphoma. In this study, we aimed to investigate the clinical features and therapeutic outcomes of patients with NLPHL who were diagnosed at different institutes in Turkey. We retrospectively reviewed the records of the patients diagnosed with NLPHL. Adult patients who were diagnosed after 2005 with histological confirmation were selected for the study. Forty-three patients were included in the study. Median age of patients was 37.5 years (18-70) at the time of diagnosis. About 60.5% patients were diagnosed as stage I and II NLPHL, and remaining 39.5% had stage III and IV disease. Median follow-up was 46 months. During follow-up, none of the patients died. Seven patients relapsed or progressed after initial therapy at a median of 12 months. Five of 7 relapsed/refractory patients (71.4%) were salvaged with chemotherapy only (DHAP, ICE), and the remaining 2 (28.6%) were salvaged with chemoimmunotherapy. All of relapsed/refractory patients were able to achieve complete remission after salvage therapy. Lactate dehydrogenase levels were significantly higher in patients with progressive disease compared with nonprogressive disease. Our study showed an excellent outcome with all patients alive at last contact with a median follow up of 46 months despite a wide range of different therapeutic approaches. All relapsed and refractory patients were successfully salvaged despite a low frequency of patients received immunotherapy in conjunction with chemotherapy. Our results suggest that immunotherapy may be reserved for further relapses. Copyright © 2017 John Wiley & Sons, Ltd.Item A multicenter experience of thrombotic microangiopathies in Turkey: The Turkish Hematology Research and Education Group (ThREG)-TMA01 study(Elsevier Ltd, 2018) Tekgündüz E.; Yılmaz M.; Erkurt M.A.; Kiki I.; Kaya A.H.; Kaynar L.; Alacacioglu I.; Cetin G.; Ozarslan I.; Kuku I.; Sincan G.; Salim O.; Namdaroglu S.; Karakus A.; Karakus V.; Altuntas F.; Sari I.; Ozet G.; Aydogdu I.; Okan V.; Kaya E.; Yildirim R.; Yildizhan E.; Ozgur G.; Ozcebe O.I.; Payzin B.; Akpinar S.; Demirkan F.Thrombotic microangiopathies (TMAs) are rare, but life-threatening disorders characterized by microangiopathic hemolytic anemia and thrombocytopenia (MAHAT) associated with multiorgan dysfunction as a result of microvascular thrombosis and tissue ischemia. The differentiation of the etiology is of utmost importance as the pathophysiological basis will dictate the choice of appropriate treatment. We retrospectively evaluated 154 (99 females and 55 males) patients who received therapeutic plasma exchange (TPE) due to a presumptive diagnosis of TMA, who had serum ADAMTS13 activity/anti-ADAMTS13 antibody analysis at the time of hospital admission. The median age of the study cohort was 36 (14-84). 67 (43.5%), 32 (20.8%), 27 (17.5%) and 28 (18.2%) patients were diagnosed as thrombotic thrombocytopenic purpura (TTP), infection/complement-associated hemolytic uremic syndrome (IA/CA-HUS), secondary TMA and TMA-not otherwise specified (TMA-NOS), respectively. Patients received a median of 18 (175) plasma volume exchanges for 14 (153) days. 81 (52.6%) patients received concomitant steroid therapy with TPE. Treatment responses could be evaluated in 137 patients. 90 patients (65.7%) achieved clinical remission following TPE, while 47 (34.3%) patients had non-responsive disease. 25 (18.2%) non-responsive patients died during follow-up. Our study present real-life data on the distribution and follow-up of patients with TMAs who were referred to therapeutic apheresis centers for the application of TPE. © 2018 Elsevier LtdItem Bilateral plasmacytoma of the breast(Blackwell Publishing Inc., 2018) Orguc S.; Akin M.; Aydogdu I.; Nese N.[No abstract available]Item Amlodipine-induced gingival hypertrophy(Elsevier B.V., 2020) Yolcu A.; Aydogdu I.[No abstract available]Item Signet-ring plasma cells(Massachussetts Medical Society, 2020) Yolcu A.; Aydogdu I.[No abstract available]Item Pralatrexate experience in peripheral T-cell lymphoma: A multicenter retrospective study from Turkey(Zerbinis Publications, 2021) Dal M.S.; Merdin A.; Erkurt M.A.; Ekinci Ö.; Albayrak M.; Hacıoglu S.K.; Kaya A.; Dogu M.H.; Hindilerden F.; Sarici A.; Merter M.; Aras M.R.; Caglıyan G.A.; Cakar M.K.; Aydogdu I.; Kuku I.; Korkmaz S.; Ulas T.; Eser B.; Altuntas F.Purpose: Pralatrexate is a new generation antifolate treatment agent used for the treatment of relapsed or refractory peripheral T-cell lymphomas. This study aims to determine the general characteristics of the patients receiving pralatrexate therapy in Turkey, contributing to the literature on the effectiveness of pralatrexate therapy in peripheral T-cell lymphomas by determining the response levels of such patients to the therapy. The study also attempts to clinically examine the major side effects observed in patients during treatment with pralatrexate. Methods: The study included patients with peripheral T-cell lymphoma followed up in the hematology units of several hospitals in Turkey. Overall, 20 patients aged 18 and over were included in the study. Results: The median age at the time of diagnosis was 58.5 years. PTCL-NOS (Peripheral T-cell lymphoma, not otherwise specified) subtype was in 40% of patients, making the PTCL-NOS the most common subtype in the study. In general, most patients were diagnosed with disease at an advanced stage. Pralatrexate therapy was given to the patients at a median treatment line of 3.5. Pralatrexate dose reduction was required in only 3 patients (15%). Response to pralatrexate therapy with partial remission (PR) and above was observed in 11 (55%) of the patients. Conclusion: Pralatrexate seemed to be a promising novel treatment in relapsed refractory PTCL patients. However, patients receiving pralatrexate should be followed up carefully for skin reactions, mucosal side effects, thrombocytopenia and neutropenia. © 2021 Zerbinis Publications. All rights reserved.Item Peripheral blood smear findings of COVID-19 patients provide İnformation about the severity of the disease and the duration of hospital stay(Universita Cattolica del Sacro Cuore, 2021) Berber I.; Cagasar O.; Sarici A.; Berber N.K.; Aydogdu I.; Ulutas O.; Yildirim A.; Bag H.G.G.; Delen L.A.Background: Data about the morphological changes in peripheral blood smears during COVID-19 infection and their clinical severity association are limited. We aimed to examine the characteristics of the cells detected in the pathological rate and/or appearance and whether these findings are related to the clinical course by evaluating the peripheral blood smear at the time of diagnosis in COVID-19 patients. Methods: Clinical features, laboratory data, peripheral blood smear of fifty patients diagnosed with COVID-19 by PCR was evaluated at diagnosis. Peripheral smear samples of the patients were compared with the age and sex-matched 30 healthy controls. Pictures were taken from the patient's peripheral blood smear. Patients were divided into two groups. Mild and severe stage patient groups were compared in terms of laboratory data and peripheral smear findings. The relationship between the laboratory values of all patients and the duration of hospitalization was analyzed. Results: The number of segmented neutrophils and eosinophils were low, pseudo-Pelger-Huet, pseudo-Pelger-Huet/mature lymphocyte ratio, atypical lymphocytes, monocytes with vacuoles, bands, and pyknotic neutrophils rates were higher in the peripheral blood smear of the patient group (p <0.05). Increased pseudo-Pelger-Huet anomaly, pseudo-Pelger Huet/mature lymphocyte ratio, a decreased number of mature lymphocytes, and eosinophils in peripheral blood smear were observed in the severe stage patients (p <0.05). A negative correlation was observed between hospitalization duration and mature lymphocyte and monocytes with vacuoles rates (p <0.05). Conclusion: A peripheral blood smear is an inexpensive, easily performed, and rapid test. Increased Pseudo-Pelger-Huet anomaly/mature lymphocyte rate suggests a severe stage disease, while high initial mature lymphocyte and monocytes with vacuoles rates at the time of diagnosis may be an indicator of shortened duration of hospitalization. © 2021 Universita Cattolica del Sacro Cuore. All rights reserved.Item Prospective registry of adult patients receiving therapeutic plasma exchange with a presumptive diagnosis of thrombotic microangiopathy (TMA): The Turkish hematology research and education group (ThREG)-TMA02 study(Elsevier Ltd, 2021) Akpınar S.; Tekgunduz E.; Erkurt M.A.; Esen R.; Yılmaz M.; Karakus V.; Vural F.; Gediz F.; Aydogdu I.; Kaynar L.; Korkmaz S.; Goker H.; Kelkitli E.; Ayyıldız O.; Demirkan F.Thrombotic microangiopathy(TMA) is a pathological diagnosis characterized by abnormalities of small vessels leading to microvascular thrombosis of arterioles and capillaries. The current prospective, non-interventional, multicenter (n:18) study aimed to define distribution of different TMA forms in adult Turkish patients who were referred for therapeutic plasma exchange (TPE) for a presumptive diagnosis of TMA. Patients with serum ADAMTS13 activity <5% were diagnosed as acquired thrombotic thrombocytopenic purpura (aTTP). Patients presenting with ADAMTS13 activity 6–10 % / normal renal function and patients with ADAMTS13 activity >10 %, normal renal function and no secondary TMA were treated as unclassified TMA. The study included a total of 97 patients (female: 60; male: 30) with a median age of 48 (18−74). Detailed evaluation at 1 month after hospital admission revealed aTTP, secondary TMA, infection/complement-associated hemolytic uremic syndrome and unclassified TMA in 32 (33 %), 33 (34 %), 26 (27 %) and 6 (6%) patients respectively. As subclassification of various TMAs will dictate specific therapy, proper diagnosis in a timely manner is of utmost clinical significance. © 2021 Elsevier LtdItem Prospective registry of adult patients receiving therapeutic plasma exchange with a presumptive diagnosis of thrombotic microangiopathy (TMA): The Turkish hematology research and education group (ThREG)-TMA02 study(Elsevier Ltd, 2022) Akpinar S.; Tekgunduz E.; Esen R.; Yilmaz M.; Karakus V.; Vural F.; Gediz F.; Aydogdu I.; Kaynar L.; Goker H.; Kelkitli E.; Ayyildiz O.; Demirkan F.Thrombotic microanjiopathy (TMA) is a pathological diagnosis characterized by abnormalities of small vessels leading to microvascular thrombosis of arterioles and capillaries. The current prospective, non-interventional, multicenter study aimed to define the distribution of different TMA forms in adult Turkish patients who were referred for therapeutic plasma exchange (TPE) for presumptive diagnosis of TMA. Patients with serum ADAMTS13 activity <5% were diagnosed as having acquired thrombotic thrombocytopenic purpura (aTTP). Patients presenting with ADAMTS13 activity 6–10 % / normal renal function and patients with ADAMTS13 activity >10 %, normal renal function and no secondary TMA were treated as unclassified TMA. The study included a total of 80 patients (women: 50; man: 30) with a median age of 48 (20−74). Detailed evaluation at 1 month after hospital admission revealed aTTP, secondary TMA, infection/complement-associated hemolytic uremic syndrome and unclassified TMA in 29 (36.2 %), 22 (27.5 %), 23 (28.8 %) and 6 (7.5 %) patients respectively. As subclassification of various TMAs will dictate specific therapy, proper diagnosis in a timely manner is of utmost clinical significance. © 2022Item The clinicopathological features and survival of Castleman disease: A multicenter Turkish study(Verduci Editore s.r.l, 2022) Yildiz J.; Bagci M.; Sayin S.; Kaya A.; Yilmaz F.; Ekinci O.; Dal M.S.; Basturk A.; Aydogdu I.; Albayrak M.; Dogan A.; Erkurt M.A.; Korkmaz S.; Ulas T.; Eser B.; Altuntas F.Objective: In this study, we aimed to investigate the clinicopathological features and survival of CD, which is quite rare and has many unknowns. Patients and Methods: This study was conducted by retrospectively evaluating patients diagnosed with CD in six different centers in Turkey. Results: The median age of 33 patients included in the study was 49 and 51.5% (n = 17) of these patients were women. 18 (54.5%) patients were in the hyaline vascular subtype and most of the patients were UCD (n = 20, 60.6%). The most common involvement region was head and neck (n = 19, 57.5%). The UCD group was younger than the MCD group (p=0.027). Visceral lymph node involvement was higher in MCD than in UCD (p=0.001). Similarly, it was observed that there was more hepatomegaly (p=0.035) and splenomegaly (p=0.013) in the MCD group. During the median 19.5 months follow-up period, there were no patients who died. Conclusions: It was observed that UCD and MCD are different clinical entities. Promising survival times can be achieved with surgical and systemic treatments in both subtypes of this extremely rare disease. However, this result should be supported by well-designed prospective comprehensive studies. © 2022 Verduci Editore s.r.l. All rights reserved.Item International Forum: The Turkish perspective on apheresis activity: The Turkish apheresis registry report(Elsevier Ltd, 2023) Ozatli D.; Giden A.O.; Erkurt M.A.; Korkmaz S.; Basci S.; Ulas T.; Turgut B.; Yigenoglu T.N.; Hacibekiroglu T.; Basturk A.; Dal M.S.; Namdaroglu S.; Hindilerden F.; Hacioglu S.K.; Cagliyan G.A.; Ilhan G.; Kacmaz M.; Uysal A.; Merter M.; Ekinci O.; Dursun F.E.; Tekinalp A.; Demircioglu S.; Sincan G.; Acik D.Y.; Akdeniz A.; Ucar M.A.; Yeral M.; Ciftciler R.; Teke H.U.; Umit E.G.; Karakus A.; Bilen Y.; Yokus O.; Albayrak M.; Demir C.; Okan V.; Serefhanoglu S.; Kartı S.; Ozkurt Z.N.; Eser B.; Aydogdu I.; Kuku I.; Cagirgan S.; Sonmez M.; Ozet G.; Altuntas F.Therapeutic apheresis is an extracorporeal treatment that selectively removes abnormal cells or harmful substances in the blood that are associated with or cause certain diseases. During the last decades the application of therapeutic apheresis has expanded to a broad spectrum of hematological and non-hematological diseases due to various studies on the clinical efficacy of this procedure. In this context there are more than 30 centers performing therapeutic apheresis and registered in the apheresis database in Turkey. Herein, we, The Turkish Apheresis Registry, aimed to analyze some key articles published so far from Turkey regarding the use of apheresis for various indications. © 2023 Elsevier Ltd